NCT04285086 2025-08-13
SURPASS ET
PharmaEssentia
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT02076815 2015-07-29
TEAM-ET
AOP Orphan Pharmaceuticals AG
Phase 3 Completed